Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Kerendia (finerenone) is the first drug in its class to show a benefit ... Bayer is running an open-label study – CONFIRMATION-HF – testing Kerendia with Jardiance in patients hospitalised ...
On the heels of approvals in the US, Europe and Japan, Bayer's Kerendia for ... Analysts think the drug has could reach annual sales of $2 billion or more if its label is extended to reflect ...
Besides label expansions for in-market products such as prostate cancer drug Nubeqa and kidney disease therapy Kerendia, the German pharma is prepping for the potential rollouts of two key drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback